Role of biologics and other therapies in stricturing Crohn's disease: What have we learnt so far?

Digestion

Volumn 77, Issue 1, 2008, Pages 38-47

  Sorrentino, D ^a,b  

^a UNIVERSITY OF UDINE   (Italy)

^b Cattedra di Gastroenterologia   (Italy)

Author keywords

Crohn's disease; Inflammatory and fibrotic strictures; Infliximab

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; INFLIXIMAB; MACROGOL; MANNITOL; MATRIX METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG SAFETY; ENDOSCOPIC SURGERY; FIBROGENESIS; GENETIC POLYMORPHISM; HUMAN; ILEUM DISEASE; INTESTINAL FIBROSIS; INTESTINE STENOSIS; INTESTINE STRICTURE; INTESTINE SURGERY; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS;

EID: 42349111818     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000117306     Document Type: Review

References (67)

1. Jewell DP, Satsangi J, Lobo A, et al: Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005;17:1047-1052.
2. van Dullemen HM, van Deventer SJ, Hommes DW, et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-135.
3. Targan SR, Hanauer SB, van Deventer SJ, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 1997;337:1029-1035.
4. Baert FJ, D'Haens GR, Peeters M, et al: Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-28.
5. D'Haens G, Van Deventer S, Van Hogezand R, et al: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116:1029-1034.
6. Vasilopoulos S, Kugathasan S, Saeian K, et al: Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease. Am J Gastroenterol 2000;95:2503.
7. Toy LS, Scherl EJ, Kornbluth A, et al: Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: a series of a newly described complication. Gastroenterology 2000;118:A2974.
8. REMICADE® (infliximab) Prescribing Information. August 2004.
9. Hanauer SB: Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 2003;17:131-137.
10. Rieder F, Brenmoehl J, Leeb S, et al: Wound healing and fibrosis in intestinal disease. Gut 2007;56;130-139.
11. Di Sabatino A, Pender SLF, Jackson CL, et al: Functional modulation of Crohn's disease myofibroblasts by anti-TNF antibodies. Gastroenterology 2007;133:137-149.
12. Lichtenstein GR, Olson A, Travers S, et al: Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006;101:1030-1038.
13. REMICADE® (infliximab) Prescribing Information. September 2006.
14. Stenson WF: Inflammatory bowel disease;in Yamada T, Alpers DH, Laine L, Owyang C, Powell DW (eds): Yamada Textbook of Gastroenterology. Philadelphia, Lippincott Williams &Wilkins, 1999, pp 1775-1839.
15. Geboes KP, Cabooter L, Geboes K: Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastroenterol Belg 2000;63:371-376.
16. Burke JP, Mulsow JJ, O'Keane C, et al: Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007;102:439-448.
17. Van Assche G, Geboes K, Rutgeerts P: Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 2004;10:55-60.
18. Pucilowska JB, Williams KL, Lund PK: Fibrosis in inflammatory bowel disease: cellular mediators and animal models. Am J Physiol 2000;279:G653-G659.
19. McKaig BC, Hughes K, Tighe PJ, et al: Differential expression of TGF isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol 2002;282:C172-C182.
20. Brannigan AE, Watson RW, Beddy D, et al: Increased adhesion molecule expression in serosal fibroblasts isolated from patients with inflammatory bowel disease is secondary to inflammation. Ann Surg 2002;235:507-511.
21. Leask A, Holmes A, Black CM, et al: Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 2003;278:13008-13015.
22. Bitzer M, von Gersdorff G, Liang D, et al: A mechanism of suppression of TGF beta/SMAD signaling by NF-kappa B/RelA. Genes Dev 2000;14:187-197.
23. Di Sabatino A, Ciccocioppo R, Benazzato L, Sturniolo GC, Corazza GR: Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment Pharmacol Ther 2004;19:1019-1024.
24. Sands BE, Arsenault JE, Rosen MJ, et al: Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003;98:2712-2718.
25. Prantera C, Levenstein S, Capocaccia R, et al: Prediction of surgery for obstruction in Crohn's ileitis. A study of 64 patients. Dig Dis Sci 1987;32:1363-1369.
26. Silverberg MS, Satsangi J, Ahmad T, et al: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(suppl A):5-36.
27. Louis E, Collard A, Oger AF, et al: Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-782.
28. Cosnes J, Cattan S, Blain A, et al: Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-250.
29. Alvarez-Lobos M, Arostegui JI, Sans M, et al: Crohn's disease patients carrying NOD2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005;242:693-700.
30. Laghi L, Costa S, Saibeni S, et al: Carriage of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn's ileal disease. Aliment Pharmacol Ther 2005;15;22:557-564.
31. Annese V, Lombardi G, Perri F, et al: Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease - an IG-IBD study. Am J Gastroenterol 2005;100:84-92.
32. Seiderer J, Brand S, Herrmann KA, et al: Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. Inflamm Bowel Dis 2006;12:1114-1121.
33. Louis E, Michel V, Hugot JP, et al: Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003;52:552-557.
34. Vermeire S: NOD2/CARD15: relevance in clinical practice. Best Pract Res Clin Gastroenterol 2004;18:569-575.
35. Waschke KA, Villani AC, Vermeire S, et al: Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol 2005;100:1126-1133.
36. Warnaar N, Hofker HS, Maathuis MH, et al: Matrix metalloproteinases as profibrotic factors in terminal ileum in Crohn's disease. Inflamm Bowel Dis 2006;12:863-869.
37. Bataille F, Klebl F, Rummele P, et al: Histopathological parameters as predictors for the course of Crohn's disease. Virchows Arch 2003;443:501-507.
38. Castiglione F, de Sio I, Cozzolino A, et al: Bowel wall thickness at abdominal ultrasound and the one-year-risk of surgery in patients with Crohn's disease. Am J Gastroenterol 2004;99:1977-1983.
39. Forcione DG, Rosen MJ, Kisiel JB, Sands BE: Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004;53:1117-1122.
40. Maconi G, Carsana L, Fociani P, et al: Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features. Aliment Pharmacol Ther 2003;18:749-756.
41. Maccioni F, Bruni A, Viscido A, et al: MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology 2006;238:517-530.
42. Girometti R, Zuiani C, Toso F, Brondani G, Sorrentino D, Avellini C, Bazzocchi M: MRI scoring system including dynamic motility evaluation in assessing the activity of Crohn's disease of the terminal ileum. Acad Radiol 2008;15:153-164.
43. Bodily KD, Fletcher JG, Solem CA, et al: Crohn disease: mural attenuation and thickness at contrast-enhanced CT enterography - correlation with endoscopic and histologic findings of inflammation. Radiology 2006;238:505-516.
44. Neurath MF, Vehling D, Schunk K, et al: Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 2002;97:1978-1985.
45. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ: Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-712.
46. Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426-431.
47. Holtmann MH, Neurath MF: Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis 2005;20:1-8.
48. Sorrentino D, Avellini C, Beltrami CA, et al: Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 2006;21:276-281.
49. Sorrentino D, Terrosu G, VadalàS, Avellini C: Fibrotic strictures and anti TNF-α therapy in Crohn's disease. Digestion 2007;75:22-24.
50. Knapp AB, Mirsky FJ, Dillon EH, Korelitz BI: Successful infliximab therapy for a duodenal stricture caused by Crohn's disease. Inflamm Bowel Dis 2005;11:1123-1125.
51. Pallotta N, Barberani F, Hassan NA, et al: Effect of infliximab on small bowel stenoses in Crohn's disease (abstract). Gastroenterology 2007;132:S1137.
52. Louis E, Boverie J, Dewit O, et al: Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007;70:15-19.
53. Sorrentino D, Terrosu G, Avellini C, Maiero S: Infliximab with low dose methotrexate for prevention of post surgical recurrence of ileocolonic Crohn's disease. Arch Intern Med 2007;167:1804-1807.
54. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-987.
55. Su C, Lichtenstein GR: Crohn's disease of the small bowel;in Bayless TM, Diehl AM (eds): Advanced Therapy in Gastroenterology and Liver Disease. Hamilton, Decker, 2005, pp 275-279.
56. Sachar DB: Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis 2003;9:205-209.
57. Ng SC, Kamm MA: Fulminant Crohn's colitis: when only an antibody will do. Inflamm Bowel Dis 2007;13:971-974.
58. Clark M, Colombel JF, Feagan BC, et al: American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-339.
59. Kozarek R: Stenoses of small bowel and colon; in Bayless TM, Diehl AM (eds): Advanced Therapy in Gastroenterology and Liver Disease. Hamilton, Decker, 2005, pp 351-357.
60. Ferlitsch A, Reinisch W, Püspök A, et al: Safety and efficacy of endoscopic balloon dilation for treatment of Crohn's disease strictures. Endoscopy 2006;38:483-487.
61. Pohl J, May A, Nachbar L, Ell C: Diagnostic and therapeutic yield of push-and-pull enteroscopy for symptomatic small bowel Crohn's disease strictures. Eur J Gastroenterol Hepatol 2007;19:529-534.
62. Morini S, Hassan C, Lorenzetti R, et al: Long-term outcome of endoscopic pneumatic dilatation in Crohn's disease. Dig Liver Dis 2003;35:893-897.
63. Van Assche G, Vermeire S, Rutgeerts P: Endoscopic therapy of strictures in Crohn's disease. Inflamm Bowel Dis 2007;13:359-361.
64. Koltun WA: Dangers associated with endoscopic management of strictures in IBD. Inflamm Bowel Dis 2007;13:356-358.
65. Oberhuber G, Stangl PC, Vogelsang H, et al: Significant association of strictures and internal fistula formation in Crohn's disease. Virchows Arch 2000;437:293-297.
66. Miehsler W, Reinisch W, Kazemi-Shirazi L, et al: Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis 2004;10:36-40.
67. Sorrentino D, Terrosu G, Avellini C: Risks of combining immunosuppressives and biological treatments in inflammatory bowel disease. Arch Intern Med 2008, in press.